SCHEMBL9909013

SCHEMBL9909013

CC1(C)C(C(N)=O)C1C(=O)O

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APLNR P35414 1/20 0.35
GAA P10253 1/20 0.34
SLC9A1 P19634 1/20 0.32
KDM4E B2RXH2 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP2D6 P10635 1/20 0.32
MAPT P10636 1/20 0.32
CASP1 P29466 1/20 0.32
CASP7 P55210 1/20 0.32
ACHE P22303 1/20 0.32
ALDH1A1 P00352 2/20 0.31
ALOX15 P16050 2/20 0.31
TP53 P04637 1/20 0.31
MAPK1 P28482 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
HSD17B10 Q99714 1/20 0.31
TSHR P16473 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
LMNA P02545 1/20 0.30
BLM P54132 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8615097 0.88 GAA (0.40) GAASLC9A1ACHEALDH1A1ALOX15
SCHEMBL5246594 0.88 APLNR (0.41) APLNRSLC9A1KDM4ECYP1A2CYP2D6
SCHEMBL3385056 0.88 APLNR (0.41) APLNRSLC9A1KDM4ECYP1A2CYP2D6
SCHEMBL11260869 0.88 APLNR (0.41) APLNRSLC9A1KDM4ECYP1A2CYP2D6
SCHEMBL359379 0.78 APLNR (0.35) APLNRSLC9A1KDM4ECYP1A2CYP2D6
SCHEMBL11321331 0.78 LMNA (0.37) GAASLC9A1ALOX15TDP1LMNA
SCHEMBL9862146 0.78 APLNR (0.35) APLNRSLC9A1KDM4ECYP1A2CYP2D6
SCHEMBL9862392 0.78 APLNR (0.35) APLNRSLC9A1KDM4ECYP1A2CYP2D6
SCHEMBL9909003 0.78 APLNR (0.35) APLNRSLC9A1KDM4ECYP1A2CYP2D6
SCHEMBL9862088 0.78 APLNR (0.35) APLNRSLC9A1KDM4ECYP1A2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023175526-A1 PROCESS FOR PREPARATION OF AZABICYCLO [3.1.0] HEXANE INTERMEDIATES LAURUS LABS LIMITED (IN) 2023-09-21 WO disclosed
US-8198463-B2 Process for the preparation of 6,6-dimethyl-3-azabicyclo-[3.3.0]-hexane compounds and enantiomeric salts thereof SCHERING CORPORATION (US) 2012-06-12 US disclosed
US-8198463-B2 Process for the preparation of 6,6-dimethyl-3-azabicyclo-[3.3.0]-hexane compounds and enantiomeric salts thereof SCHERING CORPORATION (US) 2012-06-12 US disclosed
US-20110092716-A1 DEHYDROHALOGENATION PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL IN PROVIDING 6,6-DIMETHYL-3-AZABICYCLO-[3.1.0]- HEXANE COMPOUNDS KWOK DAW-LONG 2011-04-21 US disclosed
US-20110092716-A1 DEHYDROHALOGENATION PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL IN PROVIDING 6,6-DIMETHYL-3-AZABICYCLO-[3.1.0]- HEXANE COMPOUNDS KWOK DAW-LONG 2011-04-21 US disclosed
US-20100256393-A1 PROCESS FOR THE PREPARATION OF 6,6- DIMETHYL-3-AZABICYCLO-[3.1.0]-HEXANE COMPOUNDS AND ENANTIOMERIC SALTS THEREOF SCHERING CORPORATION (US) 2010-10-07 US disclosed
US-20100256393-A1 PROCESS FOR THE PREPARATION OF 6,6- DIMETHYL-3-AZABICYCLO-[3.1.0]-HEXANE COMPOUNDS AND ENANTIOMERIC SALTS THEREOF SCHERING CORPORATION (US) 2010-10-07 US disclosed
US-7723531-B2 Process for the preparation of 6,6-dimethyl-3-azabicyclo-[3.1.0]-hexane compounds and enantiomeric salts thereof SCHERING CORPORATION (US) 2010-05-25 US disclosed
US-7723531-B2 Process for the preparation of 6,6-dimethyl-3-azabicyclo-[3.1.0]-hexane compounds and enantiomeric salts thereof SCHERING CORPORATION (US) 2010-05-25 US disclosed
US-20090240063-A1 Process For The Preparation Of 6,6-Dimethyl-3-Azabicyclo-[3.1.0]-Hexane Compounds ... MERCK SHARP & DOHME CORP. 2009-09-24 US disclosed
US-20090240063-A1 Process For The Preparation Of 6,6-Dimethyl-3-Azabicyclo-[3.1.0]-Hexane Compounds ... MERCK SHARP & DOHME CORP. 2009-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110092716-A1 DEHYDROHALOGENATION PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL IN PROVIDING 6,6-DIMETHYL-3-AZABICYCLO-[3.1.0]- HEXANE COMPOUNDS CYP1B1, CYP2B6, CYP2D6 APLNR 4679/4885GAA 3483/4885SLC9A1 3694/4885
US-20100256393-A1 PROCESS FOR THE PREPARATION OF 6,6- DIMETHYL-3-AZABICYCLO-[3.1.0]-HEXANE COMPOUNDS AND ENANTIOMERIC SALTS THEREOF TMT1A, HDHD5, DLST APLNR 4803/4885GAA 2118/4885SLC9A1 1137/4885
US-20090240063-A1 Process For The Preparation Of 6,6-Dimethyl-3-Azabicyclo-[3.1.0]-Hexane Compounds ... TMT1A, HDHD5, TET1 APLNR 4764/4885GAA 2453/4885SLC9A1 1871/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.